ITEMS IN AFP WITH KEYWORD:
Linagliptin reduces A1C levels to a lesser extent than first-line therapy (metformin) and is significantly more expensive than metformin and sulfonylureas. Importantly, its ability to affect diabetes-related morbidity and mortality is not known.
Dec 15, 2012 Issue
Should the Target A1C Level Be Less Than 7 Percent? Yes: This Should Be the Target for Most Patients [Editorials: Controversies in Family Medicine]
Yes: This Should Be the Target for Most Patients
Dec 15, 2012 Issue
Should the Target A1C Level Be Less Than 7 Percent? No: The Case for Modest Glycemic Control in Patients with Type 2 Diabetes [Editorials: Controversies in Family Medicine]
No: The Case for Modest Glycemic Control in Patients with Type 2 Diabetes
Painful diabetic neuropathy is a chronic disease that affects approximately 16 percent of patients who have diabetes mellitus. The American Academy of Neurology (AAN), the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM), and the American Academy of Physical Medicine and ...
Nearly one-half of persons with chronic kidney disease have diabetes mellitus. Diabetes accounted for 44 percent of new cases of kidney failure in 2008. Diabetic nephropathy, also called diabetic kidney disease, is associated with significant macrovascular risk, and is the leading cause of kidney fa...
May 1, 2012 Issue
Self-Monitoring of Blood Glucose in Patients with Type 2 Diabetes Not Using Insulin [Cochrane for Clinicians]
For patients who have had diabetes longer than one year and are not using insulin, evidence suggests that the benefit of self-monitoring of blood glucose in lowering A1C levels is small at six months and disappears by 12 months. Self-monitoring of blood glucose does not improve health-related qualit...
Caring for patients with diabetes mellitus requires addressing many issues beyond glycemic control. To help physicians provide optimal care for these patients, the American Diabetes Association (ADA) releases annual revisions to its clinical practice recommendations for standards of medical care. Th...
The American College of Physicians (ACP) has issued a clinical guideline on the use of intensive insulin therapy in hospitalized patients with or without diabetes mellitus to achieve glycemic control and improve health outcomes.
Insulin therapy is recommended for patients with type 2 diabetes mellitus and an initial A1C level greater than 9 percent, or if diabetes is uncontrolled despite optimal oral glycemic therapy. Insulin therapy may be initiated as augmentation, starting at 0.3 unit per kg, or as replacement, starting ...
What are the effects of treatments to prevent progression of nephropathy in persons with type 1 and type 2 diabetes and early and late nephropathy?